Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345404 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
A Phase 1 study of Atopic Dermatitis, sponsored by Corvus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 16
- Study locations
NCT06345404 is a Phase 1 study of Atopic Dermatitis that has completed, run by Corvus Pharmaceuticals. The registered enrollment target is 82 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (87% lower). The trial reports 16 study locations across 10 states.
The verdict
NCT06345404, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by Corvus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 16
- Study locations
Study Summary
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Soquelitinib
Study Locations (16)
California
- Clinical Site 2 - Fremont
- Clinical Site 7 - Palo Alto
- Clinical Site 13 - Pomona
New York
- Clinical Site 11 - Brooklyn
- Clinical Site 16 - New York
- Clinical Site 12 - New York
Pennsylvania
- Clinical Site 1 - Camp Hill
- Clinical Site 8 - Philadelphia
Texas
- Clinical Site 4 - Frisco
- Clinical Site 14 - San Antonio
Alabama
- Clinical Site 5 - Birmingham
Arizona
- Clinical Site 9 - Tucson
Arkansas
- Clinical Site 3 - North Little Rock
Colorado
- Clinical Site 10 - Castle Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2026-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06345404
The ClinicalTrials.gov registry entry for NCT06345404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (87% lower). The listed sponsor is Corvus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06345404 reports 16 study locations spanning 10 distinct geographic areas - top geographies include California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06345404 about?
NCT06345404 is a clinical study titled "Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD". Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
What is the current status of trial NCT06345404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2024-04-16. Estimated completion is 2026-02-24.
What conditions does trial NCT06345404 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06345404?
The interventions under investigation include: Placebo (DRUG), Soquelitinib (DRUG).
Who is sponsoring clinical trial NCT06345404?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06345404 being conducted?
This trial has 16 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.